Evaluation of the Efficacy of the ALLYANE Procedure in the Treatment of Central Motor Inhibition
1 other identifier
interventional
120
1 country
1
Brief Summary
The goal of this clinical study is to determine the effectiveness of restoring muscle strength in the management of motor inhibition when complemented by the ALLYANE process (neuro-motor reprogramming) compared to a standard management approach. The main questions it aims to answer are:
- Does the ALLYANE process lead to greater muscle strength gains compared to standard care?
- Is there a functional benefit when standard management is complemented by the ALLYANE process? The investigators will compare the group receiving standard care complemented by ALLYANE to a group receiving only standard care to evaluate if the ALLYANE process provides additional effects. Participants will:
- Undergo assessments of muscle strength.
- Receive either standard management or standard management with ALLYANE.
- Complete functional evaluations before and after treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 15, 2024
CompletedFirst Submitted
Initial submission to the registry
October 7, 2024
CompletedFirst Posted
Study publicly available on registry
January 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 20, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 20, 2026
March 7, 2025
March 1, 2025
2.9 years
October 7, 2024
March 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Muscle activity
Electromyography (EMG) during maximal voluntary isometric contraction of leg extension.
Before and 3 weeks after conventional therapy
Secondary Outcomes (1)
Strength
Before and 3 weeks after conventional therapy
Other Outcomes (1)
Lysholm Questionnaire
Before and 3 weeks after conventional therapy.
Study Arms (2)
Standard Management
ACTIVE COMPARATORThis group of patients will receive the conventional approach for managing motor inhibitions, which may include traditional physical therapy, exercises, and other rehabilitative techniques without any additional intervention.
Standard Management + ALLYANE Process
EXPERIMENTALThis group will receive the same standard management as the first group but with the addition of the ALLYANE process, a neuro-motor reprogramming technique designed to enhance muscle activation and re-establish motor control.
Interventions
Prospective study of the efficacy of the Allyane procedure after knee sprain
Active extension (e.g. by lateral raising of the quadriceps, strengthening of the quadriceps) quadriceps)
Eligibility Criteria
You may qualify if:
- Men and women aged 18 to 35 years
- No neurological history
- Have had a primary knee sprain
- Present with VMO lateralisation with or without the presence of flessum
- Quadricipital weakness between the healthy and injured limb of 50% or more as measured by a portable dynamometer
- Member of a social security scheme
You may not qualify if:
- Recurrent sprain
- Bilateral sprain
- Persons under guardianship, trusteeship or any other measure depriving them of their rights or liberty, and adults protected by law.
- Persons who do not understand French
- Knee trauma other than sprain
- Algodystrophy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Allyanelead
- Orthopedic Center Santy, Lyon, Francecollaborator
- Laboratoire Interuniversitaire de Biologie de la Motricitécollaborator
Study Sites (1)
Centre Expert du Mouvement
Lyon, 69004, France
Related Publications (1)
Dos Anjos T, Gabriel F, Vieira TD, Hopper GP, Sonnery-Cottet B. Neuromotor Treatment of Arthrogenic Muscle Inhibition After Knee Injury or Surgery. Sports Health. 2024 May-Jun;16(3):383-389. doi: 10.1177/19417381231169285. Epub 2023 Apr 27.
PMID: 37102673BACKGROUND
Related Links
Study Officials
- STUDY CHAIR
Aymeric Guillot, Pr
Laboratoire Interuniversitaire de Biologie de la Motricité
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 7, 2024
First Posted
January 14, 2025
Study Start
January 15, 2024
Primary Completion (Estimated)
December 20, 2026
Study Completion (Estimated)
December 20, 2026
Last Updated
March 7, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- The IPD and supporting information will be made available starting after statistical analysis is complete and during the process of writing the manuscript for publication. The data will remain accessible for a period of three years following the publication of the study results.
- Access Criteria
- Access to the IPD and supporting information will be granted to qualified researchers affiliated with academic, governmental, or non-profit institutions. They will have access to de-identified individual participant data, including demographic details, muscle strength assessments, functional evaluation results, and patient-reported outcomes. Access will be provided through a secure repository or data-sharing platform after approval of a data-sharing agreement. Researchers must agree to use the data solely for academic and non-commercial purposes, comply with all ethical guidelines, and acknowledge the source in any resulting publications.
The shared IPD will include key data points such as demographic information, muscle strength assessment results, functional evaluation scores, and patient-reported outcomes like Lysholm Questionnaire results. Personal identifiers will be removed to ensure participant confidentiality. Data sharing will adhere to ethical and legal requirements. Specifically, the individual participant data sets underlying results in a publication will be shared.